SCHEMBL6709151

SCHEMBL6709151

COC(=O)c1ccc2oc(-c3ccc(Cl)cc3)cc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
TNKS O95271 1/20 0.51
HDAC6 Q9UBN7 2/20 0.50
TP53 P04637 2/20 0.46
POLB P06746 1/20 0.46
THRB P10828 1/20 0.46
APP P05067 3/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
PLAU P00749 1/20 0.45
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
MAPT P10636 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
IDO1 P14902 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485304 0.93 TNKS (0.57) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL979282 0.86 APP (0.58) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL980266 0.86 TNKS (0.56) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL11845988 0.85 RAB9A (0.54) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL11845981 0.85 RAB9A (0.54) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL6709258 0.83 FFAR1 (0.56) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL3121270 0.83 NPC1 (0.52) RAB9ANPC1TNKSAPPALDH1A1
SCHEMBL3923815 0.81 APP (0.65) RAB9ANPC1TNKSHDAC6TP53
SCHEMBL8782756 0.79 MAPT (0.48) RAB9ANPC1HDAC6TP53POLB
SCHEMBL3981377 0.79 TNKS (0.69) RAB9ANPC1TNKSHDAC6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040077654-A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-22 US disclosed
EP-1351936-A1 ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
WO-2002055496-A1 ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077654-A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression LDLR, NR1H2, NCOR1 RAB9A 2511/4885NPC1 18/4885TNKS 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.